{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:29:59Z","timestamp":1790015399937,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the Netherlands, blood donor screening for hepatitis B virus (HBV) consists of HBsAg screening since the 1970s, HBV DNA minipool testing (MP\u2010NAT) since 2008, and anti\u2010HBc screening since 2011. Anti\u2010HBc reactivity causes deferral only if anti\u2010HBs titers are &lt;200\u2009IU\/mL, or when anti\u2010HBc was acquired during follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design and methods<\/jats:title><jats:p>Over 5.5 million donations from 582,459 Dutch donors were screened for HBV DNA, HBsAg, anti\u2010HBc, and, if anti\u2010HBc positive, also for anti\u2010HBs. The added value, expressed as the yield of (potentially) infectious and\/or recent HBV infections versus unnecessary donor loss, was evaluated for each of the three HBV screening tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HBV donor screening identified 89 HBV\u2010infected donors with at least two reactive HBV markers (MP\u2010NAT, HBsAg and\/or anti\u2010HBc). Single HBV\u2010marker yield was: 5 MP\u2010NAT\u2010only, 0 HBsAg\u2010only, and 20 anti\u2010HBc\u2010only donors. In addition, anti\u2010HBc screening yielded 1,067 potentially infectious donors at risk for occult HBV infection (OBI). In total, 4,126 (0.71%) donors were anti\u2010HBc\u2010reactive at first\u2010time screening, and 1,098 (0.19%) seroconverted during follow\u2010up. Anti\u2010HBc\u2010related donor loss was limited to 2,627 (0.45%) donors using anti\u2010HBs titers and two\u2010strike programs. Donor loss due to MP\u2010NAT and HBsAg screening was extremely low: 0 and 128 donors, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HBV donor screening could be limited to MP\u2010NAT and anti\u2010HBc screening. MP\u2010NAT and anti\u2010HBc improved blood safety by intercepting infectious donations from donors with recent infection or OBI, while HBsAg did not. Unnecessary donor loss related to anti\u2010HBc screening is substantial but does not endanger the continuity of the blood supply.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16420","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T07:53:38Z","timestamp":1619423618000},"page":"2116-2124","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Blood donor screening in the Netherlands: Universal <scp>anti\u2010HBc<\/scp> screening in combination with <scp>HBV<\/scp> nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-5056","authenticated-orcid":false,"given":"Thijs J.","family":"van de Laar","sequence":"first","affiliation":[{"name":"Department of Donor Medicine Research Laboratory of Blood\u2010borne Infections, Sanquin Research  Amsterdam The Netherlands"},{"name":"Department of Virology and MAT Services Sanquin Diagnostic Services  Amsterdam The Netherlands"},{"name":"Laboratory of Medical Microbiology, Onze Lieve Vrouwe Gasthuis  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris M.","family":"Hogema","sequence":"additional","affiliation":[{"name":"Department of Donor Medicine Research Laboratory of Blood\u2010borne Infections, Sanquin Research  Amsterdam The Netherlands"},{"name":"Department of Virology and MAT Services Sanquin Diagnostic Services  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke W.","family":"Molenaar\u2010de Backer","sequence":"additional","affiliation":[{"name":"Department of Virology and MAT Services Sanquin Diagnostic Services  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanneke","family":"Marijt\u2010van der Kreek","sequence":"additional","affiliation":[{"name":"Unit of Medical Donor Affairs Sanquin Blood Supply Foundation  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-7315","authenticated-orcid":false,"given":"Hans L.","family":"Zaaijer","sequence":"additional","affiliation":[{"name":"Department of Donor Medicine Research Laboratory of Blood\u2010borne Infections, Sanquin Research  Amsterdam The Netherlands"},{"name":"Department of Clinical Virology Amsterdam University Medical Centre  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13298"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12962"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1930-9"},{"key":"e_1_2_7_5_1","first-page":"301","article-title":"Rare transmission of hepatitis B virus by Dutch donors with occult infection","volume":"110","author":"Lieshout\u2010Krikke RW","year":"2016","journal-title":"Transfusion"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12744"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316490"},{"key":"e_1_2_7_8_1","first-page":"3","article-title":"A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios","volume":"112","author":"Weusten J","year":"2017","journal-title":"Vox Sang"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12556"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12890"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14784"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03909.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03031.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12446"},{"key":"e_1_2_7_15_1","first-page":"409","article-title":"Prevalence, incidence and residual risk of transfusion\u2010transmitted hepatitis B virus infection in Italy from 2009 to 2018","volume":"17","author":"Velati C","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37697335159.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12781"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.12.011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.016"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12218"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12694"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13248"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12198"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12096"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15421"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01396.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:42:59Z","timestamp":1693356179000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/trf.16420"],"URL":"https:\/\/doi.org\/10.1111\/trf.16420","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"2020-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}